Zimbabwe has rejected a significant American healthcare agreement worth 367 million US dollars (272 million pounds) spanning five years due to the United States' demand for confidential biological samples.
The decision became public after a official document dated December was disclosed, which showed Head of State Emmerson Mnangagwa believed the agreement was "skewed".
An official spokesperson has since clarified that the United States was demanding access to health data for scientific study and commercial purposes but refused to share the resulting advantages from any future vaccines.
"We must now begin the difficult and regrettable task of winding down our support in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy said the US had furnished more than $1.9bn as health assistance to Zimbabwe over the last two decades.
A physicians' group in Zimbabwe has called for further talks to find a deal acceptable to all parties so the nation's critical HIV treatment initiative can be sustained.
Wider Implications
This rejection follows a similar case in neighbouring Kenya, where a court halted a related health funding agreement after concerns were raised about the security of citizens' health data.
Since resuming office last year, US President Donald Trump has reduced foreign aid and closed the US Agency for International Development (USAID).
USAID had overseen aid for the US government, but Trump stated its expenditure was "inefficient" and his government was pursuing government-to-government deals to boost openness and responsibility.
According to reports, Sixteen nations in Africa have so far agreed to similar agreements, constituting more than $18.3bn in new funding.
Details of the Rejected Deal
This assistance for Zimbabwe would have funded "HIV/Aids treatment and prevention, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this partnership might have yielded immense benefits for Zimbabwean communities, particularly the 1.2 million men, women and children currently receiving antiretroviral therapy via US-supported initiatives," the Ambassador commented.
However, government spokesperson Nick Mangwana maintained the arrangement was "unfair".
"Zimbabwe was being asked to provide its biological resources and data over an extended period, without any corresponding guarantee of benefiting from any scientific breakthroughs – like new medicines or tests – that might result from that provided information," he stated.
"In essence, our nation would supply the basic resources for medical research without any assurance that the resulting innovations would be available to our citizens if a future pandemic emerge."
Sovereignty and Global Health
He also pointed out that the American exit from the global health body and its pursuit of bilateral health agreements were upending frameworks already established through the international organization.
Mangwana cited its Pandemic Benefit-Sharing framework designed to deal with future global health emergencies.
"This framework is designed to ensure that when a country provides its samples, the benefits – such as vaccines and treatments – are shared equitably, not commercialised solely by those with the capability to develop them."
Zimbabwe's reservations over the US deal "should not be misconstrued as hostility towards the US," Mangwana stressed.
"We are open to further dialogue with our US partners on how future collaboration might be structured in a way that honours the independence and dignity of each country."
Health Experts Response
Medical experts said it acknowledged the official position, but recommended that talks should continue since a large portion of the country's Aids initiatives were funded by external financing.
"If technical issues arise, such as those involving information security or implementation frameworks, these can often be addressed through technical clarification and negotiated safeguards," it commented.
The situation highlights the complex debate between receiving vital international aid and protecting a country's data in an increasingly data-driven world.